On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximately $18 million (before costs of the offer).
Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 million, and the Retail Entitlement Offer closed on 18 March 2022, raising approximately $4.3 million, bringing the total raise for the Entitlement Offer to $11.7 million.
For more information, download the attached PDF.
Download this document
